Sign in or create an account to add this stock to your watchlist.
About SCYNEXIS (NASDAQ:SCYX)
SCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections. The company also develops SCY-078, which is in various Phase I studies for the oral and intravenous formulations, as well as has completed Phase II study as a step-down therapy in patients with invasive candidiasis and vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC, to develop and commercialize rights for SCY-078. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SCYX
CUSIPN/A
Phone201-884-5485
Debt
Debt-to-Equity Ratio0.30
Current Ratio5.93
Quick Ratio5.93
Price-To-Earnings
Trailing P/E Ratio-1.72
Forward P/E Ratio-2.84
P/E GrowthN/A
Sales & Book Value
Annual Sales$260,000.00
Price / Sales317.07
Cash FlowN/A
Price / CashN/A
Book Value$0.79 per share
Price / Book2.23
Profitability
EPS (Most Recent Fiscal Year)($1.01)
Net Income$-25,060,000.00
Net Margins-9,450.00%
Return on Equity-78.78%
Return on Assets-43.38%
Miscellaneous
Employees19
Outstanding Shares46,840,000
SCYNEXIS (NASDAQ:SCYX) Frequently Asked Questions
What is SCYNEXIS's stock symbol?
SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."
How were SCYNEXIS's earnings last quarter?
SCYNEXIS Inc (NASDAQ:SCYX) released its quarterly earnings data on Tuesday, May, 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.06. The firm had revenue of $0.06 million for the quarter, compared to analysts' expectations of $0.10 million. SCYNEXIS had a negative net margin of 9,450.00% and a negative return on equity of 78.78%. View SCYNEXIS's Earnings History.
What price target have analysts set for SCYX?
6 analysts have issued twelve-month price targets for SCYNEXIS's shares. Their forecasts range from $4.00 to $9.00. On average, they anticipate SCYNEXIS's share price to reach $6.00 in the next year. View Analyst Ratings for SCYNEXIS.
Who are some of SCYNEXIS's key competitors?
Some companies that are related to SCYNEXIS include Catalyst Biosciences (CBIO), Corium International (CORI), Biofrontera (BFRA), Kadmon (KDMN), Tyme Technologies (TYME), Celyad (CYAD), AVEO Pharmaceuticals (AVEO), CTI BioPharma (CTIC), Cue Biopharma (CUE), Kindred Biosciences (KIN), MannKind (MNKD), Selecta Biosciences (SELB), Savara (SVRA), Viking Therapeutics (VKTX) and Scpharmaceuticals (SCPH).
Who are SCYNEXIS's key executives?
SCYNEXIS's management team includes the folowing people:
- Dr. Marco Taglietti, Chief Exec. Officer, Pres and Director (Age 58)
- Mr. Eric Francois, Chief Financial Officer (Age 43)
- Mr. David Gonzalez Angulo M.D., Chief Medical Officer (Age 53)
- Mr. Scott Sukenick J.D., Gen. Counsel
- Dr. Rajeshwar Motheram Ph.D., VP of Pharmaceutical Devel.
Has SCYNEXIS been receiving favorable news coverage?
News headlines about SCYX stock have trended very positive recently, according to Accern. Accern identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. SCYNEXIS earned a news sentiment score of 0.65 on Accern's scale. They also gave media headlines about the company an impact score of 46.69 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are SCYNEXIS's major shareholders?
SCYNEXIS's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Federated Investors Inc. PA (14.66%), Caxton Corp (4.09%), DAFNA Capital Management LLC (3.49%), CVI Holdings LLC (2.78%), Rock Springs Capital Management LP (1.75%) and Iguana Healthcare Management LLC (0.85%). Company insiders that own SCYNEXIS stock include Ann Hanham, David C Hastings, Eric Francois, Gonzalez David Angulo, Guy Macdonald, Marco Taglietti, Patrick Machado and Scott Sukenick. View Institutional Ownership Trends for SCYNEXIS.
Which institutional investors are buying SCYNEXIS stock?
SCYX stock was purchased by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Caxton Corp, CVI Holdings LLC, DAFNA Capital Management LLC, Iguana Healthcare Management LLC and Rock Springs Capital Management LP. Company insiders that have bought SCYNEXIS stock in the last two years include Ann Hanham, David C Hastings, Eric Francois, Gonzalez David Angulo, Guy Macdonald, Marco Taglietti, Patrick Machado and Scott Sukenick. View Insider Buying and Selling for SCYNEXIS.
How do I buy shares of SCYNEXIS?
Shares of SCYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is SCYNEXIS's stock price today?
One share of SCYX stock can currently be purchased for approximately $1.76.
How big of a company is SCYNEXIS?
SCYNEXIS has a market capitalization of $74.48 million and generates $260,000.00 in revenue each year. The company earns $-25,060,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. SCYNEXIS employs 19 workers across the globe.
How can I contact SCYNEXIS?
SCYNEXIS's mailing address is 101 HUDSON STREET SUITE 3610, JERSEY CITY NJ, 07302. The company can be reached via phone at 201-884-5485 or via email at [email protected]
MarketBeat Community Rating for SCYNEXIS (SCYX)
MarketBeat's community ratings are surveys of what our community members think about SCYNEXIS and other stocks. Vote "Outperform" if you believe SCYX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCYX will underperform the S&P 500 over the long term. You may vote once every thirty days.
SCYNEXIS (NASDAQ:SCYX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for SCYNEXIS in the last 12 months. Their average twelve-month price target is $6.00, suggesting that the stock has a possible upside of 240.91%. The high price target for SCYX is $9.00 and the low price target for SCYX is $4.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 2.83 | 2.83 | 2.83 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $6.00 | $8.25 | $10.00 | $9.50 |
| Price Target Upside: | 240.91% upside | 560.00% upside | 446.45% upside | 419.13% upside |
SCYNEXIS (NASDAQ:SCYX) Consensus Price Target History
SCYNEXIS (NASDAQ:SCYX) Analyst Ratings History
Show:
(Data available from 5/25/2016 forward)
SCYNEXIS (NASDAQ:SCYX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
SCYNEXIS (NASDAQ SCYX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 48.87%
SCYNEXIS (NASDAQ SCYX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/29/2018 | Gonzalez David Angulo | Insider | Buy | 6,000 | $1.36 | $8,160.00 | 101,790 |  |
| 3/8/2018 | David C Hastings | Director | Buy | 11,834 | $1.69 | $19,999.46 | 31,834 | |
| 3/8/2018 | Eric Francois | CFO | Buy | 5,917 | $1.69 | $9,999.73 | 24,917 | |
| 3/8/2018 | Gonzalez David Angulo | Insider | Buy | 14,790 | $1.69 | $24,995.10 | 88,790 | |
| 3/8/2018 | Marco Taglietti | CEO | Buy | 100,000 | $1.69 | $169,000.00 | 404,000 | |
| 3/8/2018 | Scott Sukenick | General Counsel | Buy | 2,959 | $1.69 | $5,000.71 | 2,959 | |
| 9/22/2017 | Marco Taglietti | CEO | Buy | 10,000 | $2.23 | $22,300.00 | 303,000 | |
| 8/23/2017 | Marco Taglietti | CEO | Buy | 5,000 | $1.85 | $9,250.00 | 287,007 | |
| 8/15/2017 | Marco Taglietti | CEO | Buy | 10,000 | $1.61 | $16,100.00 | 287,000 | |
| 8/11/2017 | Gonzalez David Angulo | Insider | Buy | 10,000 | $1.55 | $15,500.00 | 72,000 | |
| 6/21/2017 | David C Hastings | Director | Buy | 20,000 | $1.75 | $35,000.00 | 20,000 | |
| 5/12/2017 | Gonzalez David Angulo | Insider | Buy | 15,000 | $1.70 | $25,500.00 | 62,000 | |
| 5/12/2017 | Marco Taglietti | CEO | Buy | 25,000 | $1.69 | $42,250.00 | 277,000 | |
| 12/21/2016 | Marco Taglietti | CEO | Buy | 25,000 | $3.30 | $82,500.00 | 251,000 | |
| 12/16/2016 | Gonzalez David Angulo | Insider | Buy | 4,000 | $3.25 | $13,000.00 | 46,000 | |
| 9/15/2016 | Patrick Machado | Director | Buy | 40,000 | $2.94 | $117,600.00 | 60,000 | |
| 6/30/2016 | Gonzalez David Angulo | Insider | Buy | 36,950 | $2.22 | $82,029.00 | 8,850 | |
| 6/24/2016 | Eric Francois | CFO | Buy | 15,000 | $2.39 | $35,850.00 | 15,000 | |
| 6/24/2016 | Guy Macdonald | Director | Buy | 40,000 | $2.39 | $95,600.00 | 40,000 | |
| 6/24/2016 | Marco Taglietti | CEO | Buy | 100,000 | $2.39 | $239,000.00 | 225,000 | |
| 5/25/2016 | Ann Hanham | Director | Buy | 4,225 | $3.64 | $15,379.00 | 4,225 | |
| 5/25/2016 | Marco Taglietti | CEO | Buy | 5,754 | $3.26 | $18,758.04 | 124,754 | |
| 5/24/2016 | Marco Taglietti | CEO | Buy | 5,500 | $3.37 | $18,535.00 | 119,000 | |
| 5/23/2016 | Marco Taglietti | CEO | Buy | 7,500 | $3.14 | $23,550.00 | 110,500 | |
| 5/19/2016 | Marco Taglietti | CEO | Buy | 6,000 | $3.07 | $18,420.00 | 106,000 | |
| 11/24/2015 | Marco Taglietti | CEO | Buy | 22,733 | $6.79 | $154,357.07 | 100,000 | |
| 8/31/2015 | Marco Taglietti | CEO | Buy | 25,000 | $7.82 | $195,500.00 | 77,267 | |
| 8/28/2015 | Marco Taglietti | CEO | Buy | 2,267 | $7.08 | $16,050.36 | 52,267 | |
| 8/26/2015 | Marco Taglietti | CEO | Buy | 50,000 | $7.07 | $353,500.00 | 50,000 | |
| 5/7/2014 | Jean-Yves Nothias | Director | Buy | 50,000 | $10.00 | $500,000.00 | | |
| 5/7/2014 | Ventech Capital Ii | Major Shareholder | Buy | 28,000 | $10.00 | $280,000.00 | | |
(Data available from 1/1/2013 forward)
SCYNEXIS (NASDAQ SCYX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | SCYNEXIS to Present SCY-078 Data at ASM Microbe 2018
finance.yahoo.com - May 24 at 5:46 PM |
 | SCYNEXIS (SCYX) Now Covered by Analysts at Ladenburg Thalmann
www.americanbankingnews.com - May 24 at 1:14 PM |
| Brokerages Anticipate SCYNEXIS Inc (SCYX) Will Announce Quarterly Sales of $80,000.00
www.americanbankingnews.com - May 24 at 9:05 AM |
| Free Daily Technical Summary Reports on Mylan and Three Other Generic Drugs Stocks
finance.yahoo.com - May 24 at 8:15 AM |
| SCYNEXIS to Participate in a Panel at the 2018 BIO International Convention
finance.yahoo.com - May 23 at 5:40 PM |
| What’s Behind the 28% Hike in SCYNEXIS Stock Last Week?
finance.yahoo.com - May 22 at 8:16 AM |
| Zacks: Analysts Expect Scynexis (SCYX) to Post -$0.14 Earnings Per Share
www.americanbankingnews.com - May 22 at 1:16 AM |
| Seaport Global Securities Comments on Scynexis' Q2 2018 Earnings (SCYX)
www.americanbankingnews.com - May 18 at 7:08 AM |
| Financial Analysis: Retrophin (RTRX) versus Scynexis (SCYX)
www.americanbankingnews.com - May 13 at 11:16 PM |
| Scynexis (SCYX) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 9 at 1:31 PM |
 | SCYNEXIS beats by $0.08, misses on revenue
seekingalpha.com - May 9 at 8:15 AM |
| Scynexis: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 8:14 AM |
| SCYNEXIS Reports First Quarter 2018 Financial Results and Provides Company Update
finance.yahoo.com - May 8 at 5:45 PM |
| Scynexis (SCYX) Earns Buy Rating from Analysts at Roth Capital
www.americanbankingnews.com - May 8 at 2:46 PM |
| Scynexis (SCYX) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - May 8 at 11:02 AM |
 | Roth Capital Assumes SCYNEXIS (SCYX) at Buy
www.streetinsider.com - May 8 at 8:12 AM |
 | Benzinga's Top Upgrades, Downgrades For May 7, 2018
www.benzinga.com - May 7 at 5:43 PM |
| Scynexis' (SCYX) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - May 7 at 2:58 PM |
| UPDATE: HC Wainwright Starts SCYNEXIS (SCYX) at Buy
www.streetinsider.com - May 7 at 8:15 AM |
| Scynexis (SCYX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - May 5 at 3:33 AM |
| Scynexis (SCYX) Upgraded to Hold by ValuEngine
www.americanbankingnews.com - May 2 at 6:02 PM |
| Scynexis (SCYX) Granted FDA Fast Track & Qualified Infectious Disease Product Designation for Oral SCY-078
www.streetinsider.com - May 2 at 8:17 AM |
 | SCYNEXIS's Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention ...
www.prnewswire.com - May 1 at 5:21 PM |
| SCYNEXIS's Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention of Recurrent VVC
finance.yahoo.com - May 1 at 5:21 PM |
| Achaogen (AKAO) vs. Scynexis (SCYX) Financial Analysis
www.americanbankingnews.com - April 26 at 7:46 AM |
| SCYNEXIS Data Presentations at ECCMID 2018 Show SCY-078 Potent and Synergistic Antifungal Activity Against Aspergillus and Pneumocystis
finance.yahoo.com - April 23 at 8:12 AM |
| Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical ...
www.prnewswire.com - April 20 at 5:25 PM |
| Generic Drugs Stocks' Research Reports Released on Mylan, Momenta Pharma, Rigel Pharma, and SCYNEXIS
www.prnewswire.com - April 13 at 8:15 AM |
| Research Analysts Offer Predictions for Scynexis' Q1 2018 Earnings (SCYX)
www.americanbankingnews.com - April 12 at 7:09 AM |
| SCYNEXIS to Present SCY-078 Data at the 28th European Congress of Clinical Microbiology and Infectious Disease ...
www.prnewswire.com - April 10 at 5:33 PM |
| Scynexis (SCYX) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 10 at 9:13 AM |
| Scynexis (SCYX) Receives New Coverage from Analysts at Seaport Global Securities
www.americanbankingnews.com - April 10 at 8:30 AM |
| SCYNEXIS to Present SCY-078 Data at the 28th European Congress of Clinical Microbiology and Infectious Disease (ECCMID)
finance.yahoo.com - April 10 at 8:19 AM |
| Scynexis (SCYX) Earns Buy Rating from Analysts at Guggenheim
www.americanbankingnews.com - April 5 at 10:14 PM |
| Form 4 SCYNEXIS INC For: Apr 02 Filed by: Macdonald Guy
www.streetinsider.com - April 5 at 10:04 AM |
| Form 4 SCYNEXIS INC For: Mar 29 Filed by: Angulo Gonzalez David
www.streetinsider.com - April 2 at 8:32 AM |
| SCYNEXIS to Present at the 17th Annual Needham Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - March 22 at 8:21 AM |
| SCYNEXIS Presents Data at Superbugs and Superdrugs 2018 - PR Newswire (press release)
www.prnewswire.com - March 21 at 8:42 AM |
| SCYNEXIS to Present at the 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 21 at 8:42 AM |
| SCYNEXIS Presents Data at Superbugs and Superdrugs 2018
finance.yahoo.com - March 20 at 5:21 PM |
| SCYNEXIS Reports Full Year 2017 Financial Results and Provides Company Update
finance.yahoo.com - March 13 at 7:22 PM |
| Gonzalez David Angulo Buys 14,790 Shares of SCYNEXIS Inc (SCYX) Stock
www.americanbankingnews.com - March 12 at 10:17 AM |
| SCYNEXIS Inc (SCYX) Director Buys $19,999.46 in Stock
www.americanbankingnews.com - March 12 at 10:17 AM |
| SCYNEXIS Inc (SCYX) CEO Buys $169,000.00 in Stock
www.americanbankingnews.com - March 12 at 10:16 AM |
| SCYNEXIS to Present at the 30th Annual ROTH Conference - PR Newswire (press release)
www.prnewswire.com - March 7 at 8:13 AM |
| SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants - PR Newswire (press release)
www.prnewswire.com - March 7 at 8:13 AM |
| Scynexis (SCYX) Prices $30M Public Offering of Common Stock, Warrants - StreetInsider.com
www.streetinsider.com - March 7 at 8:13 AM |
| SCYNEXIS to Present at the 30th Annual ROTH Conference
finance.yahoo.com - March 7 at 8:13 AM |
 | BRIEF-SCYNEXIS Announces Pricing Of $30 Mln Public Offering Of Common Stock And Warrants
www.reuters.com - March 6 at 5:43 PM |
| Scynexis (SCYX) Prices $30M Public Offering of Common Stock, Warrants
www.streetinsider.com - March 6 at 5:43 PM |
SCYNEXIS (NASDAQ:SCYX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
SCYNEXIS (NASDAQ:SCYX) Income Statement, Balance Sheet and Cash Flow Statement
SCYNEXIS (NASDAQ SCYX) Stock Chart for Friday, May, 25, 2018
Loading chart…
